Protective effects of Bombyx mori, quercetin and benazepril against doxorubicin induced cardiotoxicity and nephrotoxicity  by Nazmi, Abdul S. et al.
Journal of Saudi Chemical Society (2016) 20, S573–S578King Saud University
Journal of Saudi Chemical Society
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEProtective eﬀects of Bombyx mori, quercetin and
benazepril against doxorubicin induced
cardiotoxicity and nephrotoxicity* Corresponding author. Fax: +91 11 26059663.
E-mail address: aknajmi@jamiahamdard.ac.in (A.K. Najmi).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.jscs.2013.04.001
1319-6103 ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Abdul S. Nazmi a, Shibli J. Ahmad a, Krishna K. Pillai a, Mohammad Akhtar a,
Aftab Ahmad b, Abul K. Najmi a,*a Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, Hamdard University, New Delhi 110062, India
b Health Information Technology Department, Jeddah Community College, King Abdul Aziz University, Jeddah-21589, Kingdom
of Saudi ArabiaReceived 15 February 2013; accepted 3 April 2013
Available online 22 April 2013KEYWORDS
Benazepril;
Bombyx mori;
Cardiotoxicity;
Doxorubicin;
Nephrotoxicity;
QuercetinAbstract The present study was conducted with the aim of evaluating the protective effects of Bom-
byx mori, quercetin and benazepril on doxorubicin (DXR) induced cardiotoxicity and nephrotoxi-
city in rats. B. mori, quercetin and benazepril were administered for 7 days, and a single
intravenous injection of 10 mg/kg body weight of DXR on day ﬁve. The animals were sacriﬁced
48 h after DXR administration. DXR produced a signiﬁcant elevation in the malondialdehyde
(MDA) level and signiﬁcantly inhibited the activity of glutathione (GSH) in the heart and the kidney
followed by the activity of catalase (CAT) in the heart tissue with a signiﬁcant rise in the serum levels
of aspartate transaminase (AST), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creat-
inine and a reduction in serum GSH levels indicating acute cardiac toxicity. B. mori, quercetin and
benazepril pretreatment signiﬁcantly reduced the MDA concentration and ameliorated the inhibi-
tion of cardiac GSH and CAT activity. B. mori, quercetin and benazepril also signiﬁcantly improved
the serum levels of AST, LDH, BUN, creatinine and GSH in DXR-treated rats. Furthermore, his-
tological examination of the heart sections conﬁrmed the myocardial injury with DXR administra-
tion, and the near normal pattern with B. mori, quercetin and benazepril pretreatment. The results
provide clear evidence that the B. mori, quercetin and benazepril pretreatments offer signiﬁcant pro-
tection against DXR-induced enzymatic changes in serum, cardiac and renal tissue damage.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Doxorubicin (DXR) is an anthracycline, glycoside antineo-
plastic agent which is most widely used in the chemotherapy
of cancer. It has been used successfully to produce improve-
ment in many neoplastic conditions like acute lymphoblastic
S574 A.S. Nazmi et al.and acute myeloblastic leukemias (Bernard, 1967; Cortex et al.,
1972). However, the clinical use of this drug is limited by its
side effects which are cardiomyopathy and nephropathy. The
exact mechanism of doxorubicin-induced toxicity remains un-
clear, but most studies support the view that oxidative stress
plays an important role in the pathogenesis of DXR toxicity
(Kumar et al., 2001).
Bombyx mori (called silk cocoon or ‘‘Abresham’’ in the
Unani system), is a major constituent of ‘‘Khamira Abresham
Hakim Arshad Wala’’ a common traditional Unani medicine
(Goyal et al., 2010). Kurioka et al. isolated three quercetin gly-
cosides, quercetin 5-O-beta-D-glucoside, quercetin 7-O-beta-D-
glucoside, and quercetin 40-O-beta-D-glucoside, and two
kaempferol glycosides, kaempferol 5-O-beta-D-glucoside and
kaempferol 7-O-beta-D-glucoside, from an ethanolic extract
of yellow cocoon shell of the silkworm. It was suggested that
potent antioxidative activity in the cocoon is mainly due to ﬂa-
vonoid compounds since free radical scavenging activity was
found in the cocoon ﬂavonoids (Kurioka and Yamazaki,
2002).
Quercetin is one of the most common food ﬂavonoid. The
ﬂavonoids frequently occur as glycosides (De Silva et al.,
1998). Quercetin is able to suppress free radical processes at
three stages; the formation of superoxide ion, the generation
of hydroxyl (or cryptohydroxyl) radicals in the Fenton reac-
tion and the formation of lipid peroxy radicals (Hansaki
et al., 1994).
Benazepril is a non-sulfydryl, long acting Angiotensin con-
verting enzyme inhibitor prodrug, which is converted in vitro
into its active diacid form, benazeprilat. Benazepril is a safe
and effective antihypertensive agent that does not cause any
adverse renal or metabolic effects (Tramonti et al., 1996). Re-
cently, benazepril has shown protective effects against chronic
renal ﬁbrosis and renal glomerulosclerosis (Chen et al., 2007).
The effectiveness of B. mori, quercetin and benazepril
against DXR-induced cardiotoxicity and nephrotoxicity as
well as oxidative stress related parameters has not been scien-
tiﬁcally evaluated as yet. Therefore, the aim of the present
study was to investigate the possible effect of B. mori, benazep-
ril and quercetin against DXR-induced cardiotoxicity and
nephrotoxicity in rats using biochemical markers of oxidative
stress and cellular damage.
2. Materials and methods
2.1. Experimental animals
Laboratory Wistar albino rats (either sex, 10–12 week old),
with body weight of 180–200 g, were used. Animals were accli-
matized and housed under controlled conditions of illumina-
tion (12 h light/12 h darkness) and temperature of 20–25 C.
Standard pellet diet (Amrut Rat Feed, Mfd. By Nav Maha-
rashtra, Ltd., New Delhi) and water ad libitum were provided
to the animals throughout the study period. The study was ap-
proved by the Institutional Animal Ethics Committee of Jamia
Hamdard, New Delhi.
2.2. Drugs and chemicals
DXR, B. mori, benazepril and quercetin were obtained from
Dabur Research Foundation (India), Hamdard Wakf Labs,Delhi; Novartis India Ltd, and RRL, Jammu, respectively.
AST, LDH, BUN and creatinine assay kits were purchased
from Span Diagnostics Ltd. and J. Mitra & Co. Ltd. Delhi.
All the other chemicals used were of analytical grade.
2.3. Experimental groups
After acclimatization rats were randomly assigned into eight
groups of six animals each.
Group 1 received normal saline (1 ml/kg body weight), or-
ally daily for 7 days and served as the control group.
Group 2 received a single dose of DXR (10 mg/kg i.v.), on
day ﬁve, 2 hours after saline administration, served as the toxic
control group.
Group 3 received B. mori (3 ml/kg per day p.o. for 7 days)
and DXR (10 mg/kg i.v. on 5th day).
Group 4 received benazepril (10 mg/kg per day p.o. for
7 days) and DXR (10 mg/kg i.v. on 5th day).
Group 5 received quercetin (2 mg/kg per day p.o. for
7 days) and DXR (10 mg/kg i.v. on 5th day).
Group 6 received B. mori per se (3 ml/kg per day p.o. for
7 days).
Group 7 received benazepril per se (10 mg/kg per day p.o.
for 7 days).
Group 8 received quercetin per se (2 mg/kg per day p.o. for
7 days).
Rats were sacriﬁced under ether anesthesia 48 h after DXR
administration. Ether had no effect on the activity of the drugs
and animals were sacriﬁced immediately afterward. Blood
samples were collected from carotid artery and sera were sep-
arated by centrifugation at 3000 rpm for 10 min and frozen at
20 C for estimation of serum activities of AST, LDH, BUN,
creatinine and GSH. The heart and the kidney were isolated,
weighed, washed in ice-cold physiological saline and homoge-
nized for biochemical and histopathological studies.
2.4. Biochemical estimations
Serum AST (Reitman and Frankel, 1957), LDH (Lum and
Gambino, 1974), potassium (Ahmad et al., 2002), creatinine
(Bones and Tausky, 1945), blood GSH (Beutler et al., 1963),
urea (Teitz, 1976) and tissue TBARS (Ohkawa et al., 1979),
GSH (Sedlack and Lindsay, 1968), and catalase (Luck, 1971)
were estimated according to the reported procedures.
2.5. Histopathological examination of heart sections
Formalin ﬁxed heart sections were embedded in parafﬁn wax,
serially sectioned (3–5 lm), and stained with Hematoxylin and
Eosin, for assessment of histopathological changes (Belur
et al., 1990).3. Statistical analysis
Statistical analysis was carried out using Graph pad prism 3.0
(Graph pad software San Diego, CA). All results are expressed
as mean ± S.E.M. Groups of data were compared with the
analysis of variance (ANOVA) followed by Dunnett’s t-test
to identify signiﬁcance among groups. Values were considered
statistically signiﬁcant when p< 0.05.
Table 2 Effect of DXR, Bombyx mori, quercetin and bena-
zepril on serum BUN and creatinine levels.
Treatment regimen Urea (mmols/L) Creatinine (lmols/L)
Control 8.93 ± 0.91 57.33 ± 7.51
DXR 19.80 ± 1.1** 213.58 ± 7.98**
Bombyx mori+DXR 10.62 ± 0.43** 129.24 ± 12.36**
Quercetin + DXR 13.87 ± 1.1** 151.70 ± 10.25*
Benazepril + DXR 12.64 ± 0.69** 139.87 ± 5.37**
Bombyx mori per se 9.85 ± 0.23 70.72 ± 12.23
Quercetin per se 11.14 ± 0.43 65.33 ± 10.65
Benazepril per se 9.29 ± 0.88 71.45 ± 3.05
DXR (toxic control) is compared with the normal control. Bombyx
mori, benazepril and quercetin are compared with the toxic control.
* P< 0.05.
** P< 0.01.
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Doxorubicin induced cardiotoxicity and nephrotoxicity are
very well documented phenomenon in humans (Lefrak et al.,
1973) as well as in different animal models (Singal et al.,
1987; Siveski-Iliskovic et al., 1995). The mechanism of DXR-
induced toxicity is not fully understood. One hypothesis pro-
posed for this mechanism is the involvement of free radicals
(Myers, 1982). This has been shown to occur through the met-
abolic breakdown of DXR to a free radical state that interacts
with molecular oxygen to generate peroxides (Singal et al.,
1987). These highly toxic reactive oxygen species react with cel-
lular molecules including nucleic acids, protein and lipids,
causing cell damage (Yin et al., 1998). Administration of
DXR in combination with agents that would block its free-
radical-mediated toxicity without affecting its anti-tumor
activity, and prevent its oxidative stress and tissue injury,
might serve as a novel combination.
In our investigation, we focused on studying the changes in
cardiac enzyme activity, hypertrophy of residual myocytes and
antioxidant activity. The results of this study have established
that a single dose of DXR (10 mg/kg, i.v.) induces acute car-
diotoxicity and nephrotoxicity in rats which are in agreement
with previous studies (Pinna et al., 1994; Dziegel et al.,
2002). The results of this study also showed an obvious cardiac
protection by prophylactic administration of B. mori, benazep-
ril and quercetin for 7 days before DXR treatment, as evi-
denced by biochemical and histopathological changes in the
heart and the kidney. In recent studies ‘‘Khamira Abresham
Hakim Arshad Wala’’, has shown protective effects in isopro-
terenol-induced myocardial necrosis (Goyal et al., 2010) and
Alzheimer’s disease (Khan et al., 2006). B. mori is the major
constituent in this formulation.
Increased activity of serum AST and LDH is a well-known
diagnostic marker of myocardial function. It has been reported
that AST and LDH are released from the heart into blood
stream, increasing the concentration in serum (Deepa and Var-
alakhshmi, 2003). In the present study, a marked elevation
(P< 0.01) in the activities of AST and LDH in the serum of
DXR-intoxicated rats was observed. Pretreatment with B.
mori, benazepril and quercetin resulted in signiﬁcant reduction
(P< 0.05) in the activities of AST and LDH toward near nor-
mal as compared with toxic control rats. This result could be
due to protective effects of Bombyx mori, benazepril and quer-
cetin on the myocardium, thus restricting the leakage of AST
and LDH (Table 1).Table 1 Effect of DXR, Bombyx mori, quercetin and benazepril on
Treatment regimen AST (lkat/L) LDH
Control 0.852 ± 0.079 70 ±
DXR 5.142 ± 0.147** 724 ±
Bombyx mori+DXR 1.871 ± 0.06** 393 ±
Quercetin + DXR 2.82 ± 0.39* 487 ±
Benazepril + DXR 2.34 ± 0.14* 352 ±
Bombyx mori per se 1.08 ± 0.15 96 ±
Quercetin per se 0.974 ± 0.18 103 ±
Benazepril per se 0.865 ± 0.28 94.9 ±
DXR (toxic control) is compared with the normal control. Bombyx mori
* P< 0.05.
** P< 0.01.Potassium (normal values: 3.5–5.0 mmoles/L) is a major
component in cardiac function. Elevated potassium level,
called hyperkalemia occurring due to decrease in renal func-
tion, is the most likely cause and others are major infection,
gastrointestinal bleeding, and rapid protein breakdown which
may also cause elevated potassium levels. Electrocardiogram
changes can be seen in this condition. In our study, we found
an increase (P< 0.01) in serum K+ levels in DXR-treated rats
that reveals the adverse effect of DXR on cardiac and renal
cells. The signiﬁcant prevention (P< 0.01) of DXR-induced
changes in K+ level by B. mori, benazepril and quercetin
showed the prominent protective effect on cardiac and renal
cells (Table 1).
Furthermore, we observed an increase (P< 0.01) in the
levels of nephrocyte injury markers like urea and creatinine
in the serum of DXR-treated rats indicating the nephrotoxic
effect of DXR in rats. The attenuation (P< 0.01) of DXR-in-
duced rise in serum urea and creatinine levels by B. mori, bena-
zepril and quercetin indicates the reno-protective effect of
these drugs (Table 2).
GSH functions as a free radical scavenger in the repair of
radical induced cellular damage. Others also have reported
low levels of GSH as observed during an increase in oxidative
stress caused by doxorubicin administration (Singal and Ilisko-
vic, 1998). The attenuation (P< 0.01) of glutathione depleting
effects of DXR by B. mori, benazepril and quercetin in blood,
heart and kidney tissues reveals the antioxidant effects pro-
duced by these drugs (Figs. 1 and 2).serum AST, LDH, GSH and K+ levels.
(U/L) GSH (mg%) K+ (mmols/L)
2.51 7.46 ± 1.44 4.0 ± 0.31
10.16** 3.46 ± 0.17* 8.18 ± 0.76**
8.8** 11.76 ± 0.98** 4.86 ± 0.23**
45.6* 13.81 ± 0.88** 3.86 ± 0.1**
8.1** 10.76 ± 1.32** 4.7 ± 0.28**
8.79 8.79 ± 0.43 3.28 ± 0.42
13.2 10.44 ± 1.04 4.1 ± 0.21
11.1 8.94 ± 0.21 4.26 ± 0.27
, benazepril and quercetin are compared with the toxic control.
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Figure 1 Effect of DXR, Bombyx mori, quercetin and benazepril on the heart and kidney MDA level. DXR (toxic control) is compared
with the normal control. Bombyx mori, benazepril and quercetin are compared with the toxic control. Values are statistically signiﬁcant at
*P< 0.05, **P< 0.01.
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Figure 2 Effect of DXR, Bombyx mori, quercetin and benazepril on the heart and kidney GSH level. DXR (toxic control) is compared
with the normal control. Bombyx mori, benazepril and quercetin are compared with the toxic control. Values are statistically signiﬁcant at
*P< 0.05, **P< 0.01.
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Figure 3 Effect of DXR, Bombyx mori, quercetin and benazepril on heart catalase activity. DXR (toxic control) is compared with the
normal control. Bombyx mori, benazepril and quercetin are compared with the toxic control. Values are statistically signiﬁcant at
*P< 0.05, **P< 0.01.
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Figure 4 (A–E) Histopathological slides of rat heart
(H&E · 100). (A) Control rat heart shows normal cellular
morphology. (B) DXR treated rat heart shows a small cluster of
myocardial ﬁbers, widening of myoﬁbrils (indicated by arrow A),
loss of myoﬁbril integration and cell shrinkage (indicated by arrow
B). (C) Bombyx mori+DXR treated rat heart showing cardiac
muscle ﬁber of normal shape size and conﬁguration. (d) Querce-
tin + DXR treated rat heart showing normal myocardium. No
vacuolated ﬁbers are observed. (E) Benazepril + DXR treated rat
heart showing normal cardiac muscle ﬁber but at some places
hyalinaization of myoﬁbres are observed.
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and Yamazaki, 2002; Hirayama et al., 2006). It is suggestedthat potent antioxidative activity in the cocoon is mainly due
to ﬂavonoid compounds since free radical scavenging activity
was found in the cocoon ﬂavonoids (Kurioka and Yamazaki,
2002). Thus, the protective effect produced by B. mori and
quercetin might be due to their antioxidant property.
DXR can undergo a two-electron reduction to form alkyl-
ating quinone and methides. As quinones, they are also able to
undergo redox cycling to generate oxygen radicals, which can
in turn lead to the induction of lipid peroxidation. Increased
levels of oxygen species due to doxorubicin have been detected
by an increase in tissue malondialdehyde (MDA) formation,
which is a breakdown product of lipid peroxidation (Alafeefy,
2011; Myers et al., 1977). Signiﬁcant elevation (P< 0.01) in
the level of MDA after DXR administration was observed in
our study. The reduction (P< 0.01) in levels of MDA in heart
and kidney tissues of rats pretreated with B. mori, benazepril
and quercetin in DXR-treated rats suggests the anti-lipid per-
oxidative property of test drug that protects the myocardium
from lipid peroxidation (Figs. 1 and 2).
CAT is an endogenous antioxidant enzyme present in the
cytoplasm that detoxiﬁes the free radical hydrogen peroxide
into water and oxygen molecules. The reduced (P< 0.01)
CAT activity in the heart of rats treated with DXR indicates
depletion of this antioxidant enzyme which is in agreement
with previous studies (Rajaprabhu et al., 2007; Arafa et al.,
2005). Pretreatment with B. mori, benazepril and quercetin re-
sulted in restoration (P< 0.01) of CAT activity which reﬂects
the possible protective effect of B. mori, benazepril and querce-
tin (Fig. 3).
Furthermore, DXR-induced cardiotoxicity is manifested
by altered histopathological features including focal myocar-
dial ﬁbrosis and disorganization of the myocardium of myo-
ﬁbrillar loss (Saad et al., 2001; Yilmaz et al., 2006). In our
study the Toxic control group showed a small cluster of myo-
cardial ﬁbers, widening of myoﬁbrils, loss of myoﬁbril inte-
gration and cell shrinkage (Fig. 4B). The samples from the
groups pretreated with B. mori (Fig. 4C), benazepril
(Fig. 4D) and quercetin (Fig. 4E) before administration of
DXR all showed an improved myocardium and no evidence
of vacuolar myopathy except benazepril that showed hyalin-
ization of myoﬁbrils in some places. A normal histological
appearance of the myocardium was also observed in the nor-
mal control group. Thus, histopathological results also indi-
cate a protective effect of B. mori against DXR-induced
cardiotoxicity in rats.5. Conclusion
In conclusion, the present ﬁndings indicate that Bombyx mori,
benazepril and quercetin have a protective effect against the
acute model of DXR-induced cardiotoxicity and nephrotoxi-
city in rats.
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